Literature DB >> 17678644

Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis.

Mitsuru Shiokawa1, Minoru Narita, Atsushi Nakamura, Kazuhiro Kurokawa, Tadao Inoue, Tsutomu Suzuki.   

Abstract

In the management of pain, nausea and vomiting are some of the most distressing adverse effects induced by opioids. In the present study, we investigated the effect of the dopamine system-stabilizer aripiprazole on morphine-induced emesis. Morphine induced retching and vomiting in a dose-dependent manner in ferrets. The emetic effect of morphine was significantly suppressed by pretreatment with either the dopamine receptor antagonist haloperidol or aripiprazole. These results suggest that the co-administration of aripiprazole may be useful for reducing the severity of morphine-induced emesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17678644     DOI: 10.1016/j.ejphar.2007.05.027

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  1 in total

1.  In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile.

Authors:  Shuhei Suzuki; Masahiro Yamamoto; Keita Togashi; Tomomi Sanomachi; Asuka Sugai; Shizuka Seino; Takashi Yoshioka; Chifumi Kitanaka; Masashi Okada
Journal:  Oncotarget       Date:  2019-05-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.